FDA Seeks Input on Next COVID Vaccine Recipe for 2026
Published Date: 4/27/2026
Notice
Summary
The FDA is holding a public meeting on May 28, 2026, to decide the 2026-2027 formula for the COVID-19 vaccine. This affects everyone who gets vaccinated, as the vaccine’s ingredients might change to better fight the virus. The FDA wants your thoughts before May 27, 2026, so jump in and share your comments online—no cost, just your voice!
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
FDA to Select 2026-2027 COVID Vaccine Formula
On May 28, 2026, the FDA advisory Committee will meet to discuss and make recommendations on the 2026-2027 formula for COVID-19 vaccines for use in the United States. This selection could change the vaccine ingredients used for people who get COVID-19 shots in the U.S.
Public Comment Docket for Vaccine Formula
FDA opened a public docket (Docket No. FDA-2026-N-3962) for comments on the 2026-2027 COVID-19 vaccine formula. The docket closes May 27, 2026; comments submitted on or before May 21, 2026 will be provided to the Committee, and electronic comments are accepted until 11:59 p.m. ET on May 27, 2026.
How to Make Oral Presentations to the Committee
Individuals may request to make formal oral presentations during the open public hearing (scheduled about 1:00–2:00 p.m. ET on May 28, 2026). Interested speakers must notify the contact person and submit a brief statement and contact details by 12 p.m. Eastern Time on May 18, 2026; the contact person will notify speakers by 6 p.m. ET on May 20, 2026. If requests exceed available time, FDA may run a lottery.
Virtual Meeting Access and Disability Accommodations
The May 28, 2026 meeting will be conducted via online teleconference/video (with captions), streamed at the provided YouTube link, recorded, and FDA will provide disability accommodations if requested at least 7 days before the meeting. FDA waived certain in-person location requirements to allow the online format.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-08121, Agency Information Collection Activities: Proposed New Information Collection Activity; Comment Request: Proposed Study Entitled “Pilot Study Examining Interpersonal Violence Experienced by Young Adults”
The Department of Justice wants to start a new study to learn about violence young adults face in their daily lives. They’re asking for public feedback until May 27, 2026, to make sure the questions are clear and not too much work. This study will help improve how we understand and prevent violence, with no big costs or time demands for participants.
Next: 2026-08123, New Postal Products
The Postal Service has asked for approval to add or change special deals for competitive mail services. This affects businesses and customers who use these services, possibly changing prices or options soon. The public can comment before the Postal Regulatory Commission makes a final decision.